ABSTRACT
The writing of vocational college thesis is the maln way to test whether the students are able to analyze and solve practical problems with the professional knowledge and skills they've learnt, as well as improve the capability of production and practice. This paper analyzes the present situation of the thesis written by higher vocational college students majoring in pharmaceutical sci-ences, and figures out the four kinds of evaluation standards about graduation thesis for students in various pharmaceutical fields with different problems. The four kinds of evaluation standards includes key point analysis on Standard Operation Procedure (SOP), planning strategy for pharmaceutical mar-keting, investigation of rational use of drugs in hospitals and subject research. The author puts forward the solving method for the problem, and formulate the evaluation requirements.
ABSTRACT
Objective To detect the recombinant intermediates of hepatitis B virus (HBV) between genotype B and C in vitro. Methods Vector Plenti6/V5-D-topo-X was genetically modified by genotype B and C to transfect HepG2 cells. Then the HepG2 cells were amplified and sequence of the nucleic acid after the transinfection was tested and compared with RDP3Beta40 software package and bootscanning procedure in SimPlot program package. Results Three recombinant intermediates of HBV between genotype B and C were identified in vitro. Genotype C in the precore region plus the core gene spanning nucleotide positions from 1740-1838 to 2443-2485 contributed to the recombination with genotype B. Isolate R1 recombinant intermediate had 2 break points at nt2170-2172 and nt2188-2189. Nucleic acid changed from CAC to TGT and from GA to AC, respectively. Isolate R2 recombinant intermediate had a break point at nt1740-1 838, and 3 bases changed in different nucleic acid sites: from A to T at nt1740, from C to T at nt1753, and from G to A at nt1838, respectively. Isolate R3 recombinant intermediate had a break point at nt2443-2483, and 4 bases changed in different nucleic acid sites: from C to T at nt2443, from A to G at nt2452, from T to C at nt2480, and from C to T at nt2483, respectively. Conclusion The recombinant intermediates of HBV between genotype B and C have been detected in vitro and the changes have been identified in the precore region plus the core gene in genotype B and C.
ABSTRACT
OBJECTIVE:To optimize the formulation of paeonol-SPE7-?-CD inclusion complex tablets.METHODS:The formulation was optimized by orthogonal test with dissolution rate serves as index and the amount of adhesive(10% starch paste),disintegrant(dry starch)and lubricant(magnesium stearate)served as major factors,meanwhile a verification test was conducted.RESULTS:The optimum formulation of paeonol-SPE7-?-CD inclusion complex tablets was as follows:paeonol-SPE7-?-CD 106.2 g,lactose 48.7 g,10% starch paste 3.0 g,dry starch 6.0 g,and magnesium stearate 0.1g.The mean dissolution rate was 95.56% for three batches of samples prepared under the above condition.CONCLUSION:The optimized formulation is ideal and feasible.
ABSTRACT
OBJECTIVE:To optimize the formulation technology of paeonol-?-cyclodextrin inclusion compound. METHODS: The formulation technology of paeonol-?-cyclodextrin inclusion compound was optimized by performing orthogonal experiment with the amount of ?-cyclodextrin,the solid-liquid ratio (ratio of ?-cyclodextrin to paeonol alcohol solution),the concentration of the envelop liquid (alcohol) as factors and the ultrasonic time was studied by single factor test and with the utilization ratio and entrapment efficiency of paeonol as indexes for evaluation. Meanwhile,a verification test was performed. RESULTS: The optimal formulation technology was as follows: the amount of ?-cyclodextrin was 8 g;the solid-liquid ratio was 1∶3;the concentration of the alcohol was 40% and the ultrasounding time was 40 min. The verification test revealed that the labeled contents were about 90% for all samples (4 batches). CONCLUSION: The optimized formulation technology is simple and reasonable,and it is applicable for the preparation of paeonol-?-cyclodextrin inclusion compound.